A key part of this will be the implementation of the readability guideline on package leaflets and the feedback from interested parties • increased use of ‘modular’ European public assessment reports (EPAR), permitting access to the most up to date medicinal product information in all 11 official EU languages and increased standardisation of the scientific content and presentation • ongoing analysis of positive opinions and withdrawals to better understand negative outcomes and analysis of authorisations under exceptional circumstances, including fulfilment of obligations and exploration of whether new information led to a changed benefit/risk ratio